2 -heteroaryl- pyrrolo [3, 4-c] pyrrole derivatives and their use as scd inhibitorsThe invention relates to compounds of formula (I), in which the groups R1, M, A, B, D, L and R are defined as cited in the description, and to their physiologically compatible salts. The compounds aresuitable e.g. for treating metabolic syndrome, insulin resistance, obesity and diabetes.Formula i compound:wherein:r is hydrogen, (c 1-c 16)-alkyl, (c 1-c 5)-alkyl oxy, (c 1-c 5)-alkylthio, (c 1-c 5)-alkylamino, two-(c 2-c 8)-alkylamino, (c 0-c 4)-alkylidene group-(c 6-c 10)-aryl, (c 0-c 4)-alkylidene group-(c 5-c 12)-heteroaryl, (c 0-c 4)-alkylidene group-(c 3-c 12)-heterocyclic radical, (c 0-c 4)-alkylidene group-(c 3-c 12)-cycloalkyl, two ring (c 8-c 14) ring system, wherein aryl, heteroaryl, heterocyclic radical, cycloalkyl or two are encircled (c 8-c 14) ring system can be by following group list or polysubstituted: halogen, (c 1-c 6)-alkyl, (c 1-c 3)-alkyl oxy, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino, list-(c 1-c 6)-alkyl amino-carbonyl, two-(c 2-c 8)-alkyl amino-carbonyl, (c 1-c 6)-alkoxy carbonyl, (c 1-c 6)-alkyl-carbonyl, cyano group, trifluoromethyl, trifluoromethyl oxygen base, (c 1-c 6)-alkyl sulphonyl or amino-sulfonyl; r1 is hydrogen, (c 1-c 10)-alkyl, (c 1-c 10)-alkyl oxy, amino, list-(c 1-c 10)-alkylamino, two-(c 2-c 12)-alkylamino, wherein alkyl can be replaced by following group: halogen, (c 1-c 6)-alkyl, (c 1-c 3)-alkyl oxy, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino ,-(c 6-c 10)-aryl ,-(c 5-c 12)-heteroaryl ,-(c 3-c 12)-heterocyclic radical or-(c 3-c 12)-cycloalkyl, wherein aryl, heteroaryl, heterocyclic radical or cycloalkyl can be chosen wantonly separately by following group list or polysubstituted: halogen, (c 1-c 6)-alkyl, (c 1-c 3)-alkyl oxy, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino; r2 is hydrogen, (c 1-c 16)-alkyl, (c 0-c 4)-alkylidene group-(c 6-c 10)-aryl; r3 is hydrogen, (c 1-c 6)-alkyl, (c 1-c 3)-alkyl oxy, hydroxyl, (c 1-c 6)-alkyl thiol, amino, (c 1-c 6)-alkylamino, two-(c 2-c 12)-alkylamino, cyano group, (c 1-c 6)-alkyl-carbonyl, halogen, trifluoromethyl, trifluoromethyl oxygen base, (c 1-c 6)-alkyl sulphonyl, amino-sulfonyl; a is o, s, n (r2), c (r3), c (r3)=c (r3), nh=c (r3), c (r3)=nh, nh=nh;b is c (r3), n (r2);d is c (r3), n (r2);wherein at least one must be a nitrogen among member a, b or the d;n is 1 or 2 independently of one another;l be valence link ,-c (=o)-,-c (=s)-,-c (=o)-n (r2)-,-c (=o)-o-,-s (o) 0-2-,-s (o) 0-2-n (r2)-, wherein one or more ring memberses can be n (r3), o, s or-c (=o)-monocycle or bicyclic ring system; m is-c (=o)-n (r2)-,-n (r2)-c (=o)-,-s (o) 0-2-,-s (o) 0-2-n (r2)-,-n (r2)-s (o) 0-2-,-c (=o)-o-,-o-c (=o)-; and the salt of physical compatibility.
2-헤테로아릴-피롤로[3,4-ｃ]피롤 유도체 및 ＳＣＤ 억제제로서의 이들의 용도본 발명은 화학식 I의 화합물 및 이들의 생리학적으로 혼용 가능한 염에 관한 것이다. 상기 화합물은, 예를 들면, 대사 증후군, 인슐린 내성, 비만 및 당뇨병을 치료하기에 적합하다. 화학식 I  위의 화학식 I에서, R1, M, A, B, D, L 및 R은 본 명세서에서 정의한 바와 같다. 화학식 I의 화합물 및 이들의 생리학적으로 혼용 가능한 염. 화학식 I [이미지] 위의 화학식 I에서, R은 수소, (C1-C16)-알킬, (C1-C5)-알킬옥시, (C1-C5)-알킬티오, (C1-C5)-알킬아미노, 디-(C2-C8)-알킬아미노, (C0-C4)-알킬렌-(C6-C10)-아릴, (C0-C4)-알킬렌-(C5-C12)-헤테로아릴, (C0-C4)-알킬렌-(C3-C12)-헤테로사이클릴, (C0-C4)-알킬렌-(C3-C12)-사이클로알킬, 바이사이클릭 (C8-C14) 환 시스템이고, 상기 아릴, 헤테로아릴, 헤테로사이클릴, 사이클로알킬 또는 바이사이클릭 (C8-C14) 환 시스템은 할로겐, (C1-C6)-알킬, (C1-C3)-알킬옥시, 하이드록실, (C1-C6)-알킬-머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, 모노-(C1-C6)-알킬아미노-카보닐, 디-(C2-C8)-알킬아미노카보닐, (C1-C6)-알콕시카보닐, (C1-C6)-알킬카보닐, 시아노, 트리플루오로메틸, 트리플루오로-메틸옥시, (C1-C6)-알킬설포닐 또는 아미노설포닐에 의해 일치환 또는 다치환될 수 있고, R1은 수소, (C1-C10)-알킬, (C1-C10)-알킬옥시, 아미노, 모노-(C1-C10)-알킬-아미노, 디-(C2-C12)-알킬아미노이고, 상기 알킬은 할로겐, (C1-C6)-알킬, (C1-C3)-알킬옥시, 하이드록실, (C1-C6)-알킬-머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, -(C6-C10)-아릴, -(C5-C12)-헤테로아릴, -(C3-C12)-헤테로사이클릴 또는 -(C3-C12)-사이클로알킬에 의해 치환될 수 있고, 상기 아릴, 헤테로아릴, 헤테로사이클릴 또는 사이클로알킬은 각각 임의로 할로겐, (C1-C6)-알킬, (C1-C3)-알킬옥시, 하이드록실, (C1-C6)-알킬-머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노에 의해 일치환 또는 다치환될 수 있고, R2는 수소, (C1-C16)-알킬, (C0-C4)-알킬렌-(C6-C10)-아릴이고, R3은 수소, (C1-C6)-알킬, (C1-C3)-알킬옥시, 하이드록실, (C1-C6)-알킬-머캅토, 아미노, (C1-C6)-알킬아미노, 디-(C2-C12)-알킬아미노, 시아노, (C1-C6)-알킬카보닐, 할로겐, 트리플루오로메틸, 트리플루오로-메틸옥시, (C1-C6)-알킬설포닐, 아미노설포닐이고, A는 O, S, N(R2), C(R3), C(R3)=C(R3), NH=C(R3), C(R3)=NH, NH=NH이고, B는 C(R3), N(R2)이고, D는 C(R3), N(R2)이고, A, B 또는 D 중의 하나 이상은 질소이어야 하며, n은 각각 독립적으로 1 또는 2이고, L은 결합, -C(=O)-, -C(=S)-, -C(=O)-N(R2)-, -C(=O)-O-, -S(O)0-2-, -S(O)0-2-N(R2)-, 모노사이클릭 또는 바이사이클릭 환 시스템(여기서, 하나 이상의 환원은 N(R3), O, S 또는 -C(=O)-일 수 있다)이고, M은 -C(=O)-N(R2)-, -N(R2)-C(=O)-, -S(O)0-2-, -S(O)0-2-N(R2)-, -N(R2)-S(O)0-2-, -C(=O)-O-, -O-C(=O)-이다.